亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

濟南偉都化工有限公司  

原料藥,中間體,吡啶類,硼酸類

搜索
新聞分類
聯系方式
  • 聯系人:姚娟
  • 電話:0531-88873476
  • 郵件:wedosusan@126.com
  • 傳真:0531-88873470
  • QQ:309536088
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 公司新聞 > 鹽酸表阿霉素,56390-09-1,Epirubicin hydrochloride
公司新聞
鹽酸表阿霉素,56390-09-1,Epirubicin hydrochloride
2011-01-21IP屬地 火星231

鹽酸表阿霉素,56390-09-1,Epirubicin hydrochloride
 
英文名  Epirubicin hydrochloride
別名  (8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxynaphthacene-5,12-dione hydrochloride
產品名稱  鹽酸表柔比星; 鹽酸表阿霉素; (8S,10S)-10-[(3'-氨基-2',3',6'-三脫氧-alpha-L-阿拉伯吡喃糖基)-O-]-6,8,11-三羥基-8-羥乙酰基-1-甲氧基-7,8,9,10-四氫并四苯-5,12-二酮鹽酸鹽

分子式  C27H29NO11.HCl
分子量  579.99
CAS 登錄號  56390-09-1

©2025 濟南偉都化工有限公司 版權所有   技術支持:化工網   訪問量:107157  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |